Global Epidermolysis Bullosa Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Epidermolysis Bullosa treatment during 2019. Clinical development activities are being undertaken by more than 25 companies including Abeona Therapeutics Inc, Aegle Therapeutics Corp, Amryt Pharma plc, Anterogen Co Ltd, Azitra Inc and others.
A Significant contribution to the Epidermolysis Bullosa pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Epidermolysis Bullosa pipeline included 26 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Epidermolysis Bullosa condition and increased access to investments is encouraging growth of Epidermolysis Bullosa drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Epidermolysis Bullosa drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Epidermolysis Bullosa therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Epidermolysis Bullosa pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Epidermolysis Bullosa. Further, orphan drug status, fast track designation, grants awarded and other special status for Epidermolysis Bullosa pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Epidermolysis Bullosa pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Epidermolysis Bullosa Pipeline candidates-
A Significant contribution to the Epidermolysis Bullosa pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Epidermolysis Bullosa pipeline included 26 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Epidermolysis Bullosa condition and increased access to investments is encouraging growth of Epidermolysis Bullosa drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Epidermolysis Bullosa drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Epidermolysis Bullosa therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Epidermolysis Bullosa pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Epidermolysis Bullosa. Further, orphan drug status, fast track designation, grants awarded and other special status for Epidermolysis Bullosa pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Epidermolysis Bullosa pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Epidermolysis Bullosa Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Epidermolysis Bullosa drugs
- Late phase: Phase 3 and in-approval Epidermolysis Bullosa drugs
- Company overview
- Snapshot
- Epidermolysis Bullosa therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Epidermolysis Bullosa- Disease Overview
2.2 Epidermolysis Bullosa- Pipeline Snapshot
2.3 Epidermolysis Bullosa- Pipeline Drugs by Phase
2.4 Epidermolysis Bullosa- Pipeline Drugs by Company
2.5 Epidermolysis Bullosa- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Abeona Therapeutics Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.2 Aegle Therapeutics Corp Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.3 Amryt Pharma plc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.4 Anterogen Co Ltd Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.5 Azitra Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.6 Berg Pharma LLC Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.7 BridgeBio Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.8 Constant Pharmaceuticals LLC Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.9 CSL Ltd Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.10 Ember Therapeutics Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.11 Fibrocell Science Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.12 GlaxoSmithKline Plc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.13 Holostem Terapie Avanzate Srl Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.14 Immusoft Corp Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.15 InMed Pharmaceuticals Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.16 Krystal Biotech Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.17 Life Sciences Institute Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.18 MallInckrodt Plc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.19 Mesoblast Ltd Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.20 Palvella Therapeutics LLC Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.21 Phoenix Tissue Repair Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.22 ProQR Therapeutics NV Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.23 RegeneRx Biopharmaceuticals Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.24 RHEACELL GmbH & Co KG Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.25 Shionogi & Co Ltd Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.26 TWi Biotechnology Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Epidermolysis Bullosa- Phase 1 Drug Details
4.2 Epidermolysis Bullosa- Phase 1 Drug Overview
4.3 Epidermolysis Bullosa- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Epidermolysis Bullosa- Phase 2 Drug Details
5.2 Epidermolysis Bullosa- Phase 2 Drug Overview
5.3 Epidermolysis Bullosa- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Epidermolysis Bullosa- Phase 3 Drug Details
6.2 Epidermolysis Bullosa- Phase 3 Drug Overview
6.3 Epidermolysis Bullosa- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Epidermolysis Bullosa- Pre-clinical Phase Drug Details
7.2 Epidermolysis Bullosa- Pre-clinical Phase Drug Overview
7.3 Epidermolysis Bullosa- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Epidermolysis Bullosa- Disease Overview
2.2 Epidermolysis Bullosa- Pipeline Snapshot
2.3 Epidermolysis Bullosa- Pipeline Drugs by Phase
2.4 Epidermolysis Bullosa- Pipeline Drugs by Company
2.5 Epidermolysis Bullosa- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Abeona Therapeutics Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.2 Aegle Therapeutics Corp Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.3 Amryt Pharma plc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.4 Anterogen Co Ltd Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.5 Azitra Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.6 Berg Pharma LLC Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.7 BridgeBio Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.8 Constant Pharmaceuticals LLC Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.9 CSL Ltd Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.10 Ember Therapeutics Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.11 Fibrocell Science Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.12 GlaxoSmithKline Plc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.13 Holostem Terapie Avanzate Srl Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.14 Immusoft Corp Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.15 InMed Pharmaceuticals Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.16 Krystal Biotech Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.17 Life Sciences Institute Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.18 MallInckrodt Plc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.19 Mesoblast Ltd Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.20 Palvella Therapeutics LLC Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.21 Phoenix Tissue Repair Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.22 ProQR Therapeutics NV Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.23 RegeneRx Biopharmaceuticals Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.24 RHEACELL GmbH & Co KG Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.25 Shionogi & Co Ltd Epidermolysis Bullosa Drug Pipeline, H2- 2019
3.26 TWi Biotechnology Inc Epidermolysis Bullosa Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Epidermolysis Bullosa- Phase 1 Drug Details
4.2 Epidermolysis Bullosa- Phase 1 Drug Overview
4.3 Epidermolysis Bullosa- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Epidermolysis Bullosa- Phase 2 Drug Details
5.2 Epidermolysis Bullosa- Phase 2 Drug Overview
5.3 Epidermolysis Bullosa- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Epidermolysis Bullosa- Phase 3 Drug Details
6.2 Epidermolysis Bullosa- Phase 3 Drug Overview
6.3 Epidermolysis Bullosa- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Epidermolysis Bullosa- Pre-clinical Phase Drug Details
7.2 Epidermolysis Bullosa- Pre-clinical Phase Drug Overview
7.3 Epidermolysis Bullosa- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
